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Abstract To identify cis-acting sequences transcriptionally
regulating the human calcitonin receptor (hCTR) gene, hCTR
promoter/luciferase gene constructs were transiently or stably
transfected into hCTR-positive and -negative cell lines. Lucifer-
ase assays demonstrated that the proximal hCTR promoter
(hCTRP1) was transcriptionally active in all cell lines tested.
High-level hCTRP1 activity depended on an 11 bp Sp1/Sp3
binding site. Electrophoretic mobility shift assay showed that
this region bound the transcription factors Sp1 and Sp3. We
further showed that hCTRP1 was strongly activated by the 11
bp Sp1/Sp3 binding site in hCTRP1/luciferase-, Sp1-transfected
Drosophila S2 cells. Bisulphite-mediated sequencing of genomic
DNA from hCTR-expressing and -non-expressing cell lines
demonstrated that the endogenous hCTRP1 was hypomethy-
lated in all cell lines tested. These results suggest that the
hCTRP1 is activated by the tissue-ubiquitous transcription fac-
tor Sp1 and that an epigenetic process unrelated to CpG meth-
ylation represses its activity in hCTR-negative tissues.
/ 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
The calcitonin receptor (CTR) is a member of the seven
trans-membrane domain G protein-coupled receptor super-
family [1,2]. Its binding to calcitonin (CT), a 32 amino acid
peptide hormone, stimulates activation of the adenylate cy-
clase/cAMP protein kinase A pathway [3], the phosphoinosi-
tide-dependent phospholipase C pathway and the protein ki-
nase C pathway [4,5]. CT inhibits osteoclast-mediated bone
resorption and increases Ca2þ excretion by the kidney [6^8].
High-a⁄nity receptors for CT have been identi¢ed in a variety
of tissues such as brain [9,10], testis [11], spermatozoa [12],
kidney [13,14], osteoclasts [15^17], skeletal muscle [18], breast
cancer cell lines and human primary breast cancer [19^21].
Recently, we identi¢ed the presence of CTRs in the chronic
myelogenous leukaemia cell line K562 [22].
Both human and mouse CTR (hCTR and mCTR) genes
have been shown to be regulated by multiple promoters.
The mCTR gene contains three promoters: P1, P2 and P3.
Data suggest that the P3 promoter is only transcriptionally
active in osteoclasts [23]. At least two promoters, hCTRP1
(proximal) and hCTRP2 (distal), have been identi¢ed and
shown to regulate hCTR gene expression [24]. Transcriptional
analysis of a 4.9 kb DNA fragment (4.5 kb 5P-£anking region
+ 441 bp 3P-£anking region) containing hCTRP1 and
hCTRP2 in transgenic mice suggest its transcriptional activity
is restricted to CTR-expressing tissues [25]. Deletion mapping
of this fragment in transfected hCTR-positive T47D breast
cancer cells demonstrated that only 97 bp of hCTRP1 5P-
£anking region (cap=0) contains at least 70% of the tran-
scriptional activity of the 4.9 kb hCTR promoter fragment
[24]. However, transcriptional regulatory elements within
this region and the transcription factors they interact with
have not yet been identi¢ed.
In this paper, we employed hCTRP1 deletional analysis and
electrophoretic mobility shift assays (EMSA) to identify DNA
sequences and the transcription factors they interact with that
regulate hCTRP1 transcriptional activity. The role Sp1/Sp3
transcription factors play in hCTRP1 transcriptional activity
was examined and bisulphite-mediated sequencing of hCTRP1
was carried out to determine if CpG methylation of hCTRP1
was associated with repression of its transcriptional activity in
non-hCTR-expressing cell lines.
2. Materials and methods
2.1. Cell lines and culture
hCTR-positive human breast cancer cell lines T47D and MCF-7
and the hCTR-negative human foreskin cell line HS27 were main-
tained in Dulbecco’s modi¢ed Eagle’s medium supplemented with
10% foetal calf serum, 100 Wg/ml penicillin and 100 U/ml streptomy-
cin. The hCTR-negative embryonic kidney cell line HEK293 was
maintained as above except Earle’s modi¢ed essential medium
(MEM) supplemented with MEM non-essential amino acids was em-
ployed. Drosophila Schneider 2 (S2) cells were maintained in Schnei-
der’s Drosophila medium (Gibco) supplemented with 10% heat-in-
activated foetal calf serum, 100 Wg/ml penicillin and 100 U/ml
streptomycin.
2.2. DNA transfections
For transient transfections in mammalian cell lines, cells were trans-
fected with 1^2 Wg of speci¢c hCTR/luciferase construct, 0.2 Wg of a
co-transfection control plasmid pRLTK (Promega) and Fugene 6
(Roche) according to the manufacturers’ instructions. Luciferase as-
says were performed employing a dual luciferase receptor assay sys-
tem (Promega) and a Turner Design TD-20/20 luminometer. For sta-
ble transfection assays, T47D and HEK293 cells were transfected with
2 Wg of speci¢c plasmid as above. Pools of G418 (1.2 mg/ml)-resistant
clones for each construct were harvested and luciferase assays per-
formed as above on 20 Wg of lysed cell extract. For transient trans-
fections into Schneider cells, 0.5 Wg of various hCTR constructs were
co-transfected with varying amounts of pPacSp1 and/or pPacSp3 and
1 Wg of a L-galactosidase co-transfection control plasmid p97b (kind
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gifts of Prof. G. Suske). Transfections and luciferase assays were
performed as above.
2.3. Generation of hCTR/luciferase constructs
An hCTR/luciferase construct containing 4.5 kb of 5P-£anking re-
gion (relative to hCTRP1’s most 5P start site of transcription) and 441
bp of 3P-£anking region [24] was cut with Acc65I/A£II and puri¢ed.
Sense and antisense oligos corresponding to sequences 31 to 352, 31
to 345, 31 to 336, 31 to 325 (also relative to hCTRP1’s most 5P
start site of transcription) and each containing a 5P Acc65I and 3P
A£II site were annealed and ligated into the Acc65I/A£II-cut vector.
To generate an hCTR construct with 0 bp of 5P-£anking region, the
Acc65I/A£II-cut vector was puri¢ed, ¢lled in with Klenow and blunt-
end ligated. For stable transfections, luciferase construct pGL2-basic
(Promega) and pGL2-basic containing 4.5 kb or 97 bp of the hCTR 5P
region were cut with ScaI and a blunt-ended SV40 promoter/neo gene
fragment ligated in.
2.4. Nuclear extracts and EMSA
Preparation of nuclear extracts from all cell lines was carried out as
previously described [26]. Double-stranded oligonucleotides C1 5P-
CCGCCTGTCGGGAGGCGGGCGGGGGTGGGGCGGGAGCG-
CAGGC-3P ; C2 5P-CGGGCGGGGGTGGGGCGGGAGCGCAG-
GC-3P ; C3 5P-AGGCGGGAGGCGGGCGGGGGTGGGGCGGG-
A-3P ; C4 5P-CGGGGGTGGGGCGGGAGCGCAGGC-3P ; C5 5P-
AAGGGGGGCTGGCTCTCATCAATTCTGCTGCCACCTCCTC-
TGC-3P ; C6 5P-CGGGAGCGCAGGCTAGGATTGAGACTCTT-3P ;
C7 5P-CCGCCTGTCGGGAGGCGGAGGTGGGTGGGGCGGG-
AGCGCAGGC-3P ; and C8 5P-CCGCCTGTCGGGAGGCGGGCG-
GGGGTGAGGTGGGAGCGCAGGC-3P were employed for EMSA
as previously described [26]. Each double-stranded oligonucleotide has
three unpaired bases at its immediate 5P and 3P ends. A variant Sp1
binding site [27] present in oligos C1^C4 has been underlined. Sp1
goat polyclonal antibody (sc-59X) was purchased from Santa Cruz.
Sp3 antibody was a kind gift from Prof. G. Suske.
2.5. Methylation analysis of hCTRP1
A modi¢ed bisulphite-mediated genomic sequencing protocol was
employed [28]. Bisulphite-treated DNA was subjected to nested poly-
merase chain reaction (PCR) utilising two sets of primers. Set 1:
(sense) 5P-GAGGGTGTTAGGGGGAAAGAAGAGGAGT-3P ; (anti-
sense) 5P-AATCCTCCCTCTCCGCCCCTCTCCT-3P ; Set 2: (sense)
5P-TGGGATAAGGTTGTTGTGGAAA-3P ; (antisense) 5P-CCCCT-
AACTTACTTTCTACCTCCCC-3P. Qiagen Taq polymerase was em-
ployed for PCR according to the manufacturer’s instructions. PCR
products were cloned into the vector pGEM T Easy (Promega) and
DNA from 8^10 clones representing each cell line was subjected to
DNA sequence analysis.
3. Results
3.1. hCTRP1 deletional analysis in hCTR-positive/negative cell
lines
To identify cis-acting sequences regulating hCTRP1 activ-
ity, seven hCTR/luciferase constructs containing 4.5 kb, 97,
52, 45, 36, 25, and 0 bp of 5P-£anking region relative to
hCTRP1’s most 5P transcriptional start site were transiently
transfected into hCTR-positive T47D and MCF-7 cells. Lu-
ciferase assays demonstrated that a construct with only 36 bp
of 5P-£anking region was as transcriptionally active as the 4.5
kb hCTR promoter. However, the deletion of an additional 11
bp reduced expression levels to that of a construct containing
no hCTR 5P-£anking region (Fig. 1). This 11 bp region is
highly GC-rich (s 90%), contains a variant Sp1/Sp3 binding
site (GGGGTGGGGC) [27] and has potential Sp1/Sp3 bind-
ing sites at its 5P/3P junctions (see Section 2).
To assess the tissue speci¢city of hCTRP1, we transiently
transfected the above constructs into the hCTR-negative cell
lines HEK293 and HS27. Luciferase activity from all hCTRP1
constructs was identical in both hCTR-expressing and -non-
expressing cell lines. Even the construct containing 4.5 kb of
hCTR promoter and shown to contain su⁄cient 5P-£anking
region for CTR tissue-speci¢c expression in transgenic mice
[25] was transcriptionally active in hCTR-negative cells (Fig.
1). Similar results were obtained in stably transfected T47D
and HEK293 cells (data not shown). These results demon-
strate that hCTRP1 is transcriptionally promiscuous in tran-
siently or stably transfected cell lines.
3.2. EMSA analysis of the hCTRP1 activation region
To examine the interaction of the 11 bp hCTRP1 activation
region and its immediate 5P and 3P junctions with nuclear
regulatory transcription factors, three oligo probes (C2^C4)
(see Fig. 2 and Section 2) overlapping this region were syn-
thesised and EMSA carried out employing nuclear extracts
from T47D cells (Fig. 3). 32P end-labelled C2^C4 probes de-
tected three complexes (A, C and D) while probes C2 and C3
detected an additional complex (B) (see lanes 1, 6 and 11). It
should be noted that complex A is non-uniform and consists
of multiple bands. Unlabelled oligonucleotides C2 and C3
e¡ectively competed for binding of transcription factors in
all complexes (see lanes 3, 4, 8, 9, 13 and 14). Unlabelled
Fig. 1. hCTR promoter/luciferase deletion analysis in transiently
transfected cell lines. Amount of 5P-£anking region relative to
hCTRP1’s most 5P transcriptional start site (cap= 0) is indicated.
441 bp of hCTR 3P-£anking region are present in all constructs ex-
cept pGL2-basic. Relative luciferase activities were determined by
comparing luciferase activity of cells transfected with hCTR/lucifer-
ase constructs to cells transfected with the promoter-less pGL2-basic
luciferase plasmid. Background luciferase levels = 1. Cell lines em-
ployed were: T47D (T); MCF-7 (M); HS27 (H1); HEK293 (H2).
These data represent averages of three independent sets of transfec-
tions per construct all giving similar (6 10% variation) results.
Fig. 2. Positions of double-stranded oligonucleotides employed for
gel shift analysis of the hCTRP1 promoter (see Figs. 3 and 4).
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probe C4 competed for transcription factor binding in all
complexes except factor present in complex B (lanes 5 and
10). These results demonstrate that the transcription factor
in complex B binds immediately 5P to the 11 bp hCTR acti-
vation region and no factors detectably bind immediately 3P
to this region. Site-directed mutagenesis of the region just 5P
to the 11 bp hCTR activation region (see oligo C7 in Section
2) eliminated complex B while mutagenesis of the 11 bp acti-
vation region (see oligo C8 in Section 2) eliminated complex B
but not A and C (data not shown). We hypothesise that tran-
scription factors present in complex A and C, normally bind-
ing to the 11 bp activation region, are able to bind 5P to this
region when their preferred binding site(s) are mutated. Sub-
sequent displacement of transcription factor in complex B
then occurs. Probe C1 (see Fig. 2 and Section 2), which over-
laps region C2^C4, also e¡ectively competed for the binding
of transcription factors in all complexes (lanes 2, 7 and 12).
No complexes were detected when oligos C5 and C6 (see Fig.
2 and Section 2) were employed (data not shown). Together,
these results suggest that only the C2^C4 region of 97 bp of
hCTRP1 5P-£anking region detectably binds transcription fac-
tors. Furthermore, the hCTRP1 11 bp core activation region
binds factors in three complexes (A, C and D) while an addi-
tional factor present in complex B binds immediately 5P to this
region.
The 11 bp hCTR activation region contains a variant core
(GGGGTGGGGC) Sp1/Sp3 binding site. To determine if any
of the DNA/protein complexes in this region were due to the
presence of Sp1/Sp3, EMSA on C2^C4 double-stranded oli-
gonucleotides was carried out with Sp1/Sp3 antibodies (Fig.
4). At least one band comprising part of complex A on oligos
C2^C4 super-shifted with Sp1 antibodies (lanes 3, 7 and 11)
while anti-Sp3 caused complex C to disappear (lanes 4, 8 and
12). Lanes 13^15 suggested that extract from the non-hCTR-
expressing cell line HEK293 contained identical Sp1/Sp3 com-
plexes. Subsequent experiments employing HEK293 nuclear
extract and Sp1/Sp3 antibodies detected the presence of Sp1/
Sp3-containing complexes as above (data not shown). Overall,
the results suggest that the tissue-ubiquitous transcription fac-
tors Sp1 and Sp3 interact with the 11 bp hCTRP1 activation
region.
3.3. Activation of hCTRP1 in Drosophila Schneider cells
To further assess the role Sp1/Sp3 plays in hCTRP1 activ-
ity, we transfected luciferase constructs containing 97, 36, 25,
and 0 bp of hCTR 5P-£anking into Drosophila S2 cells which
are well known to lack endogenous Sp proteins. The expres-
sion levels of these constructs were examined in the presence
or absence of 5 ng of co-transfected Sp1 or Sp3 expression
constructs (Fig. 5). Luciferase activity from constructs con-
taining 97 and 36 bp of 5P-£anking region was 40-fold above
pGL2-basic background levels when co-transfected with the
Sp1 expression plasmid pPacSp1. However, deletion of the 11
bp hCTRP1 activation region caused up to a 93% drop in
hCTRP1 activity similar to expression from a construct con-
taining no hCTR 5P-£anking region. In the absence of co-
transfected pPacSp1, all constructs expressed at background
levels. Luciferase activity from constructs containing 97 and
36 bp of hCTRP1 £anking region was only two- to three-fold
above background levels when co-transfected with 5 ng of
pPacSp3. Co-transfected pPacSp3 had no detectable e¡ect
on expression from hCTR constructs containing 25 and 0
bp of 5P-£anking region. Results identical to the above were
also achieved with 2^20 ng of co-transfected pPacSp1 or
pPacSp3. However, at levels above 50 ng of pPacSp1/
pPacSp3, squelching of hCTRP1 transcriptional activity was
evident (data not shown). The results of these experiments
demonstrate that Sp1 transcriptionally activates hCTRP1 pri-
Fig. 3. EMSA of nuclear regulatory factors from T47D breast can-
cer cells binding to 32P end-labelled oligos C1^C4. Each oligo was
also employed as an unlabelled competitor. The 32P end-labelled oli-
gonucleotide probes were used at a concentration of 40 fmol/assay
and unlabelled competitor oligonucleotides were used at a concen-
tration of 2 pmol/lane. Non-speci¢c competitor poly-dIdC (0.5 Wg/
lane) was present in all lanes. Complexes A^D are indicated. This
experiment was performed at least three times, each giving similar
results.
Fig. 4. EMSA with antibodies to factors binding to 32P end-labelled
oligos C2^C4. Antibody to Sp1 or Sp3 (0.2 Wg/lane) was included in
lanes 3, 4, 7, 8, 11, 12. Nuclear extracts from T47D were employed
for lanes 2^4, 6^8, 10^12, and HEK293 for lanes 13^15. Lanes 1, 5
and 9 contain no nuclear extract. 32P end-labelled probes were used
at a concentration of 40 fmol/assay. This experiment was performed
at least three times, each giving similar results.
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marily by its interaction with the 11 bp hCTR activation
region. Transactivation by Sp1 is also mediated, although to
a much lesser extent, by sequences 3P to hCTRP1’s most 5P
start site of transcription.
To determine if Sp3 can inhibit hCTRP1 activation by Sp1
in S2 cells, varying pPacSp1 and pPacSp3 concentration ratios
were co-transfected with 0.5 Wg of 397 hCTR/luciferase con-
struct into S2 cells (see Fig. 6). The data demonstrate that
when a 3:1 ratio of pPacSp3 to pPacSp1 is transfected in
Schneider cells, hCTRP1 activity is still increased up to 45-
fold. Only when nine times more pPacSp3 is present than
pPacSp1 (9:1) is a modest but consistent decrease (25%) in
hCTRP1 activity observed.
3.4. Methylation mapping of hCTRP1
hCTRP1 contains a highly GC-rich region with multiple
CpG dinucleotides (see Fig. 7A). The 11 bp hCTRP1 activa-
tion region is present within this region. One possible mech-
anism by which hCTR gene transcription could be repressed
in speci¢c tissues in vivo is by CpG methylation of this region.
However, such a process is unlikely to be recapitulated in
transiently or stably transfected cell lines resulting in hCTRP1
transcriptional promiscuity. We therefore employed bisul-
phite-mediated sequencing of genomic DNA from hCTR-
expressing (MCF-7) and -non-expressing cells (HS27 and
HEK293) to examine the methylation state of the endogenous
hCTRP1. Sequence analysis on cloned bisulphite-treated ge-
nomic DNA from all the above cell lines demonstrated that
Fig. 5. hCTR promoter/luciferase deletion assays in Drosophila S2
cells co-transfected with or without pPacSp1/pPacSp3. Amount of
hCTR 5P-£anking region for each construct is indicated. 0.5 Wg of
each hCTR construct was co-transfected with/without 5 ng of
pPacSp1 or pPacSp3. Relative luciferase activity was compared be-
tween cells transfected with hCTR constructs (with/without co-trans-
fected pPacSp1/pPacSp1) and the promoter-less pGL2-basic plasmid
(relative luciferase activity= 1). The data are the average of three in-
dependent experiments each giving similar results.
Fig. 6. 397 hCTR/luciferase activity in transiently transfected Dro-
sophila S2 cells. Varying ratios of pPacSp1 and pPacSp3 were co-
transfected with 0.5 Wg of 397 hCTR/luciferase construct. Relative
luciferase activity was compared to cells transfected with 397
hCTR/luciferase alone (relative luciferase activity = 1). The data are
the average of three independent experiments each giving similar re-
sults.
Fig. 7. Bisulphite-mediated sequencing of the hCTRP1 promoter in
MCF-7, HS27 and HEK293 cells. A: Sequence analysis of 425 bp
of hCTRP1 5P-£anking region. Each CpG dinucleotide is numbered
and underlined. B: Methylation state of hCTRP1 CpG dinucleotides
in MCF-7, HS27 and HEK293 cells. Genomic DNA from each cell
line was bisulphite-treated and restriction enzyme-cut followed by
PCR ampli¢cation of CpG-rich region. PCR products were sub-
cloned and 8^10 clones (representing each cell type) subjected to
DNA sequence analysis.
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the entire GC-rich region of hCTRP1 is relatively methyla-
tion-free (hypomethylated) (see Fig. 7B). This suggests that a
DNA methylation-mediated mechanism is not responsible for
the repression of hCTRP1 activity in non-hCTR-expressing
cells.
4. Discussion
Although both the human and mouse CTR promoters have
been cloned and sequenced, speci¢c DNA sequences that ac-
tivate their transcription have not previously been described.
In this paper we de¢ned an 11 bp region of hCTRP1 that is
necessary for its high-level activity in a variety of cell types.
This region contains a variant Sp1/Sp3 binding site [27] along
with consensus Sp1/Sp3 binding sites at its 5P and 3P junction.
EMSAs with antibodies to Sp1 and Sp3 demonstrate these
factors bind to this activation region. Although our analysis
detected the presence of other unidenti¢ed factors (present in
complexes B and D) binding on or near this region, the well-
known ability of Sp1 to activate gene transcription combined
with our results demonstrating that Sp1 and its interaction
with the 11 bp hCTR activation region can signi¢cantly tran-
scriptionally activate hCTRP1 in Drosophila S2 cells suggests
that Sp1 plays a major role in the regulation of hCTRP1
activity. Our results showing that Sp3 only marginally in-
creases hCTRP1 activity is consistent with a variety of studies
showing Sp3 is either inactive or a weak activator of tran-
scription [29^31]. Since Sp1 and Sp3 bind to the same recog-
nition sequence, it is reasonable to hypothesise that the ratio
of Sp3 and Sp1 in di¡erent cell types can determine the level
to which the hCTRP1 promoter can be activated. However,
we found that even a 9:1 ratio of Sp3 to Sp1 caused only a
modest decrease (25%) in hCTRP1 activity. This contrasts
with Kumar and Butler [31] who demonstrated that a 3:1
ratio of Sp3 to Sp1 reduced ornithine decarboxylase promoter
activity in Schneider cells up to 97%. As the 11 bp hCTR
activation region contains a variant Sp1 binding site [27] it
is possible that Sp1 may have a greater binding a⁄nity for
this site than does Sp3. This hypothesis is currently being
tested.
Previous work with transgenic mice suggested that a DNA
fragment containing 4.5 kb of hCTR 5P-£anking region di-
rected expression of a linked lacZ gene speci¢cally to CTR-
expressing tissues in vivo [25]. The observation that the same
fragment is transcriptionally active in transiently and stably
transfected hCTR-negative cells lines suggests that sequences
which may act to repress hCTRP1 promoter activity in spe-
ci¢c tissues in vivo are not functional in stably and transiently
transfected cells. Such a lack of regulatory function in trans-
fected cells versus transgenic mice has been previously dem-
onstrated by Stanworth et al. [32]. They showed that regula-
tory elements directing human j-globin gene expression
speci¢cally to embryonic erythroid cells in transgenic mice
failed to suppress j-globin gene expression in adult transfected
erythrocytes. We hypothesise that an epigenetic process takes
place early in mouse development that acts to repress hCTR
gene expression in speci¢c tissues. Such a process does not
appear to be recapitulated in transiently or stably transfected
cell lines.
One epigenetic process believed to play a major role in the
control of tissue-speci¢c gene regulation in vivo is cytosine
methylation. Heritable patterns of CpG methylation have
been shown to repress transcription by blocking the access
of transcription factors and inducing the formation of inactive
chromatin [33]. Recently, we demonstrated that in vitro meth-
ylation of the hCTR promoter represses its transcriptional
activity in transfected cells (unpublished results). However,
our results showing that the hCTRP1 promoter is hypomethy-
lated in both hCTR-expressing and -non-expressing cell lines
suggest that CpG methylation is not the key epigenetic mech-
anism that represses hCTR gene expression in non-hCTR-ex-
pressing tissues. Additional studies examining patterns of his-
tone acetylation and chromatin structure of the hCTR gene
are under way to elucidate the mechanism(s) that restrict the
expression of the hCTR gene in vivo.
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